Kathleen Ann Mehl, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 10100 Bay Creek Rd, Erie, MI 48133 Phone: 734-625-7973 |
News Archive
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
"As we mark World [Tuberculosis (TB)] Day on Sunday March 24, there can be no denying that TB, fueled by drug resistance, continues to pose a serious global health threat - one that must be urgently addressed," John Lechleiter, chair, president and CEO of Eli Lilly and Company and chair of the board of PhRMA, writes in a Forbes opinion piece, adding, "With resistance spreading, we need a renewed global commitment that combines public and private efforts to defeat TB."
Predictive Biosciences today announced that the Company will be presenting results on the development of a real-time multiplexed PCR assay for detection of FGFR3 mutations in urine and tissue at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17 - 19 in Orlando, Florida. Results will also focus on the application of the assay which is currently being used in Predictive's first commercial molecular grading product, the CertNDxTM Molecular Grading Assay.
Beckman Coulter Diagnostics is pleased to announce obtaining CE Mark and the release of its new Access TSH (3rd IS) assay for use with the company's Access Family of Immunoassay Systems.
› Verified 9 days ago